Which company does Avatrombopag come from?

In May 2018, the U.S. Food and Drug Administration (FDA) approved Dova Pharmaceuticals for the first time. Avatrombopag, manufactured by Inc., is marketed as a second-generation oral thrombopoietin receptor agonist (TPO-RA) for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled for surgery and for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an inadequate response to prior therapy.

Avatrombopag is available as20 mg oral tablet and should be taken with food. For the treatment of chronic ITP, the initial dose of avatrombopag is 20 mg (1 tablet) once daily. The dose or frequency of administration should be adjusted if necessary to maintain a platelet count of ≥50 × 109/L to reduce the risk of bleeding. The dose of avatrombopag should not exceed 40 mg per day. In patients with chronic liver disease, no dose adjustment is required.

The original drug of avatrombopag has been launched in China and has entered the scope of Class B medical insurance, but it is only reimbursed for eligible patients. The price of a common specification of 20mg*15 tablets may be more than 7,000 yuan per box, while the original drug of avatrombopag marketed overseas is even more expensive. It is understood that there are generic drugs of avatrombopag available overseas, and their pharmaceutical ingredients are basically the same as those of the original drug. For example, the price of a box of 20mg*30 tablets in Laos pharmaceutical production specifications may be around RMB 1,000 (the price may fluctuate due to exchange rates). For specific price and drug information of avatrombopag, please consult a medical consultant.